Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer

Concetta De Cicco, Laura Ravasi, Laura Zorzino, Maria Teresa Sandri, Edoardo Botteri, Fabrizio Verweij, Donatella Granchi, Ottavio De Cobelli, Giovanni Paganelli

Research output: Contribution to journalArticlepeer-review


Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients if pre-surgical identification were available. Material and Methods: Correlations between pre-surgical levels of 6 blood molecules and pathological tumour staging, post-surgical Gleason score and disease-free survival have been observed. Plasma and sera from 162 men affected by prostate adenocarcinoma were analysed with ELISA to assess levels of neovascularization-related molecule (VEGF), endothelial cell adhesion molecule (VCAM), extracellular matrix destruction-related molecules (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Results: The median values of serum determinations were for VEGF 279 pg/ml, VCAM 633 ng/ml, MMP-2 206 ng/ml and MMP-9 614 ng/ml. Plasma medians (ng/ml) were 94 for TIMP-1 and 90 for TIMP-2. Patients with VCAM values > 633 ng/ml had a worse disease-free survival than patients with values

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalCurrent Cancer Drug Targets
Issue number3
Publication statusPublished - May 2008


  • Blood marker
  • Bone metastasis
  • MMP
  • MMP-2
  • Prognosis
  • Prostate cancer
  • TIMP
  • VCAM
  • VEGF

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research


Dive into the research topics of 'Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer'. Together they form a unique fingerprint.

Cite this